Skip to main content

Table 1 Demographics and resistance outcomes

From: High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up

 

Total (n = 46)

N (%)

No resistance (n = 36)

N (%)

Any resistance (n = 9)

N (%)

Age

 18–24

19 (41)

14 (78)

4 (22)

 25–34

20 (43)

15 (75)

5 (25)

 35–44

6 (13)

6 (100)

0 (0)

 ≥ 45

1 (2)

1 (100)

0 (0)

Sex

 Male

28 (61)

21 (78)

6 (22)

 Female

18 (39)

15 (83)

3 (17)

Marital status

 Never married

11 (24)

  

 Married

23 (50)

  

 Separated/divorced/widowed

12 (26)

  

Viral load at screening

 ≤ 6 log10 copies/mL

24 (53)

19 (83)

4 (17)

 > 6 log10 copies/mL

21 (47)

16 (76)

5 (24)

NNRTI resistance mutations frequencya

 A98G

2 (4.4)

  

 E138A

3 (6.7)

  

 K101E

1 (2.2)

  

 K103N

4 (8.9)

  

 K103Q

1 (2.2)

  

 V179E

1 (2.2)

  

 V90I

1 (2.2)

  

 Y181C

1 (2.2)

  
  1. NNRTI non-nucleoside reverse transcriptase inhibitors
  2. aAmong 45 patients assessed for resistance at time of study entry